Search

Your search keyword '"Sterin, Arthur"' showing total 24 results
Start Over Author "Sterin, Arthur"
24 results on '"Sterin, Arthur"'

4. Prise en charge prophylactique, thérapeutique des complications infectieuses et vaccination des patients traités par CAR-T cells : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)

Author

Paul, Franciane, Vicente, Céline, Courbon, Corinne, Moreau, Anne-Sophie, Picard, Muriel, Pochon, Cécile, Sterin, Arthur, Tudesq, Jean-Jacques, Yakoub-Agha, Mathilde, Bay, Jacques-Olivier, and Yakoub-Agha, Ibrahim

Published
2021
Full Text
View/download PDF

6. Impact of Graft Function on Health Status and Quality of Life in Very Long-Term Survivors Who Received an HSCT for Inborn Errors of Immunity, a Prospective Study of the CEREDIH

Author

Petit, Audrey, Neven, Bénédicte, Min, Victoria, Mahlaoui, Nizar, Moshous, Despina, Castelle, Martin, Allouche, Maya, Stérin, Arthur, Visentin, Sandrine, Saultier, Paul, Boucekine, Mohamed, Shawket, Alaa Mustafa, Picard, Capucine, Auquier, Pascal, Michel, Gérard, Fischer, Alain, and Barlogis, Vincent

Published
2023
Full Text
View/download PDF

7. Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation?

Author

Le Calvez, Baptiste, Jullien, Maxime, Dalle, Jean H., Renard, Cécile, Jubert, Charlotte, Sterin, Arthur, Paillard, Catherine, Huynh, Anne, Guenounou, Sarah, Bruno, Bénédicte, Gandemer, Virginie, Buchbinder, Nimrod, Simon, Pauline, Pochon, Cécile, Sirvent, Anne, Plantaz, Dominique, Kanold, Justyna, Béné, Marie C., Rialland, Fanny, and Grain, Audrey

Published
2024
Full Text
View/download PDF

8. Interest of Cytoreductive Therapy before Allogenic Hematopoietic Stem Cell Transplantation in Childhood Myelodysplastic Syndromes: A Retrospective Study on Behalf of the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)

Author

Le Calvez, Baptiste, primary, Jullien, Maxime, additional, Dalle, Jean-Hugues, additional, Renard, Cécile, additional, Jubert, Charlotte, additional, Sterin, Arthur, additional, Paillard, Catherine, additional, Huynh, Anne, additional, Guenounou, Sarah, additional, Bruno, Benedicte, additional, Gandemer, Virginie, additional, Buchbinder, Nimrod, additional, Simon, Pauline, additional, Pochon, Cecile, additional, Sirvent, Anne, additional, Plantaz, Dominique, additional, Kanold, Justyna, additional, Rialland Battisti, Fanny, additional, and Grain, Audrey, additional

Published
2023
Full Text
View/download PDF

10. Phase I Study of a Combination of Fluvastatin and Celecoxib in Children with Relapsing/Refractory Low-Grade or High-Grade Glioma (FLUVABREX)

Author

Leblond, Pierre, primary, Tresch-Bruneel, Emmanuelle, additional, Probst, Alicia, additional, Néant, Nadège, additional, Solas, Caroline, additional, Sterin, Arthur, additional, Boulanger, Thomas, additional, Aerts, Isabelle, additional, Faure-Conter, Cécile, additional, Bertozzi, Anne-Isabelle, additional, Chastagner, Pascal, additional, Entz-Werlé, Natacha, additional, De Carli, Emilie, additional, Deley, Marie-Cécile Le, additional, Bouche, Gauthier, additional, and André, Nicolas, additional

Published
2023
Full Text
View/download PDF

11. Prise en charge du syndrome de neurotoxicité associée au traitement par cellules CAR-T chez l’adulte et l’enfant : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)

Author

Picard, Muriel, primary, Sterin, Arthur, additional, Bay, Jacques-Olivier, additional, Courbon, Corinne, additional, Moreau, Anne- Sophie, additional, Paul, Franciane, additional, Pochon, Cécile, additional, Tudesq, Jean-Jacques, additional, Vicente, Céline, additional, Yakoub-Agha, Mathilde, additional, and Yakoub-Agha, Ibrahim, additional

Published
2022
Full Text
View/download PDF

12. KMT2A-CBLrearrangements in acute leukemias: clinical characteristics and genetic breakpoints

Author

Bataller, Alex, primary, Guijarro, Francesca, additional, Caye-Eude, Aurélie, additional, Strullu, Marion, additional, Sterin, Arthur, additional, Molina, Oscar, additional, Chevallier, Patrice, additional, Zaliova, Marketa, additional, Zuna, Jan, additional, Mozas, Pablo, additional, Magnano, Laura, additional, Grardel, Nathalie, additional, Cornillet-Lefebvre, Pascale, additional, Fu, Jen-Fen, additional, Shih, Lee-Yung, additional, Boneva, Temenuzhka, additional, Nacheva, Elisabeth, additional, Beà, Silvia, additional, López-Guerra, Mònica, additional, Bueno, Clara, additional, Menéndez, Pablo, additional, Esteve, Jordi, additional, Larghero, Patrizia, additional, Meyer, Claus, additional, and Marschalek, Rolf, additional

Published
2021
Full Text
View/download PDF

15. EPCT-11. PHASE 1 STUDY OF FLUVASTATIN-CELECOXIB COMBINATION IN CHILDREN WITH RELAPSING/REFRACTORY OPTICO-CHIASMATIC LOW-GRADE GLIOMA OR HIGH-GRADE GLIOMAS (FLUVABREX): FINAL RESULTS

Author

Andrew, Nicolas, primary, Sterin, Arthur, additional, Solas, Caroline, additional, Deley, Marie-Cécile Le, additional, Probst, Alicia, additional, Aerts, Isabelle, additional, Faure-Conter, Cécile, additional, Bertozzi, Anne-Isabelle, additional, Chastagner, Pascal, additional, Entz-Werle, Natacha, additional, De Carli, Emilie, additional, Dory-Lautrec, Philippe, additional, Bouche, Gauthier, additional, and Leblond, Pierre, additional

Published
2020
Full Text
View/download PDF

16. Mesenchymal Stromal Cell (MSC) Compassionate Use in France in Treatment of Steroid-Refractory Graft-Versus-Host-Disease (GVHD) after Approval By the Expert Committee of Société Française De Greffe De Moelle Et Thérapie Cellulaire (SFGM-TC)

Author

Bosdure, Lea, primary, Blanc, Laurence, additional, Buchbinder, Nimrod, additional, Coiteux, Valerie, additional, Fossard, Gaelle, additional, Francois, Sylvie, additional, Ouachee, Marie, additional, Paillard, Catherine, additional, Pochon, Cecile, additional, Sterin, Arthur, additional, Petitpain, Nadine, additional, Bay, Jacques-Olivier, additional, Rubio, Marie Thérèse, additional, Bensoussan, Danièle, additional, and Dalle, Jean-Hugues, additional

Published
2020
Full Text
View/download PDF

18. KMT2A-CBL rearrangements in acute leukemias: clinical characteristics and genetic breakpoints

Author

Bataller, Alex, Guijarro, Francesca, Caye-Eude, Aurélie, Strullu, Marion, Sterin, Arthur, Molina, Oscar, Chevallier, Patrice, Zaliova, Marketa, Zuna, Jan, Mozas, Pablo, Magnano, Laura, Grardel, Nathalie, Cornillet-Lefebvre, Pascale, Fu, Jen-Fen, Shih, Lee-Yung, Boneva, Temenuzhka, Nacheva, Elisabeth, Beà, Silvia, López-Guerra, Mònica, Bueno, Clara, Menéndez, Pablo, Esteve, Jordi, Larghero, Patrizia, Meyer, Claus, and Marschalek, Rolf

Published
2021
Full Text
View/download PDF

19. Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies

Author

Bertoli, Sarah, primary, Sterin, Arthur, additional, Tavitian, Suzanne, additional, Oberic, Lucie, additional, Ysebaert, Loïc, additional, Bouabdallah, Reda, additional, Vergez, François, additional, Sarry, Audrey, additional, Bérard, Emilie, additional, Huguet, Françoise, additional, Laurent, Guy, additional, Prébet, Thomas, additional, Vey, Norbert, additional, and Récher, Christian, additional

Published
2016
Full Text
View/download PDF

21. Long‐term outcome after allogeneic stem cell transplantation for GATA2 deficiency: An analysis of 67 adults and children from France and Belgium.

Author

Sicre de Fontbrune, Flore, Chevillon, Florian, Fahd, Mony, Desseaux, Kristell, Poiré, Xavier, Forcade, Edouard, Sterin, Arthur, Neven, Bénédicte, Gandemer, Virginie, Thepot, Sylvain, Garnier, Alice, Lioure, Bruno, Marcais, Ambroise, Nguyen‐Quoc, Stephanie, Tavitian, Suzanne, Vincent, Laure, Donadieu, Jean, Resche Riggon, Matthieu, Chevret, Sylvie, and Pasquet, Marlene

Subjects
*GRAFT versus host disease, *STEM cell transplantation, *HEMATOPOIETIC stem cells, *ACUTE myeloid leukemia, *HEMATOPOIETIC stem cell transplantation
Abstract

Summary Modalities and timing of haematopoietic stem cell transplant (HSCT) in patients with GATA2 deficiency are still subject to debate. On June 2022, 67 patients (median age 20.6 years) underwent a first allogeneic HSCT among 21 centres. Indications for HSCT were myelodysplastic syndrome (MDS) ≤5% blasts ± immunodeficiency (66%), MDS >5% blasts (15%), acute myeloid leukaemia (19%). Conditioning regimen was myeloablative in 85% and anti‐thymocyte globulins were used in 67%. The cumulative incidence (CInc) of acute graft versus host disease (GvHD) grade II–IV and III–IV at day 100 were 42% and 13%, and CInc of chronic and extensive chronic GvHD at 2 years were 42% and 23%. CInc of relapses was 3% and 11% at 1 and 5 years. Overall survival (OS) at 1 and 5 years was 83% and 72% (median follow‐up 5.6 years). The factors associated with worse OS in multivariable analysis were the year of HSCT, a history of excess blasts before transplant and peripheral blood stem cell (PBSC) grafts. Age at HSCT, non‐myeloablative conditioning and PBSC grafts were associated with increased non‐relapse mortality. In conclusion, bone marrow monitoring to identify clonal evolution and perform HSCT before the appearance of excess blast is mandatory. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. KMT2A-CBL rearrangements in acute leukemias: clinical characteristics and genetic breakpoints

Author

Bataller, Alex, Guijarro, Francesca, Caye-Eude, Aurélie, Strullu, Marion, Sterin, Arthur, Molina, Oscar, Chevallier, Patrice, Zaliova, Marketa, Zuna, Jan, Mozas, Pablo, Magnano, Laura, Grardel, Nathalie, Cornillet-Lefebvre, Pascale, Fu, Jen-Fen, Shih, Lee-Yung, Boneva, Temenuzhka, Nacheva, Elisabeth, Beà, Silvia, López-Guerra, Mònica, Bueno, Clara, Menéndez, Pablo, Esteve, Jordi, Larghero, Patrizia, Meyer, Claus, and Marschalek, Rolf

Full Text
View/download PDF

23. [Management of neurotoxicity following CAR-T cell therapy: Recommendations of the SFGM-TC].

Author

Picard M, Sterin A, Bay JO, Courbon C, Moreau AS, Paul F, Pochon C, Tudesq JJ, Vicente C, Yakoub-Agha M, and Yakoub-Agha I

Subjects
Humans, Immunotherapy, Adoptive adverse effects, Bone Marrow Transplantation, Cytokine Release Syndrome etiology, Receptors, Chimeric Antigen therapeutic use
Abstract

The immune effector cell-associated syndrome (ICANS) has been described as the second most frequent specific complication following CAR-T cell therapy. The median time to the onset of neurological symptoms is five days after CAR-T infusion. ICANS can be concomitant to cytokine release syndrome but often follows the resolution of the latter. However, 10 % of patients experience delayed onset after 3 weeks of CAR-T cell infusion. The duration of symptoms is usually short, around five days if an early appropriate treatment is given. Symptoms are heterogeneous, ranging from mild symptoms quickly reversible (alterations of consciousness, deterioration in handwriting) to more serious forms with seizures or even a coma. The ICANS severity is currently based on the ASTCT score. The diagnosis of ICANS is clinical but EEG, MRI and lumbar punction can help ruling out alternative diagnoses. The first line treatment consists of high-dose corticosteroids. During the twelfth edition of practice harmonization workshops of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC), a working group focused its work on updating the SFGM-TC recommendations on the management of ICANS. In this review we discuss the management of ICANS and other neurological toxicities in patients undergoing of CAR-T cell therapy. These recommendations apply to commercial CAR-T cells, in order to guide strategies for the management neurological complications associated with this new therapeutic approach., (Copyright © 2022 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)

Published
2023
Full Text
View/download PDF

24. [Management of cytokine release syndrome and macrophage activation syndrome following CAR-T cell therapy: Guidelines from the SFGM-TC].

Author

Tudesq JJ, Yakoub-Agha M, Bay JO, Courbon C, Paul F, Picard M, Pochon C, Sterin A, Vicente C, Canet E, Yakoub-Agha I, and Moreau AS

Subjects
Humans, Cytokine Release Syndrome therapy, Cytokine Release Syndrome drug therapy, Neoplasm Recurrence, Local drug therapy, Immunotherapy, Adoptive adverse effects, Adrenal Cortex Hormones therapeutic use, Cell- and Tissue-Based Therapy, Receptors, Chimeric Antigen therapeutic use, Macrophage Activation Syndrome therapy, Macrophage Activation Syndrome complications
Abstract

The use of chimeric antigen receptor T cells (CAR-T) has increased since their approval in the treatment of several relapsed/refractory B cell malignancies. The management of their specific toxicities, such as cytokine release syndrome (CRS), tends to be better understood and well-defined. During the twelfth edition of practice harmonization workshops of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC), a working group focused its work on the management of patients developing CRS following CAR-T cell therapy. A special chapter has been allocated to macrophage activation syndrome (MAS), a rare but life-threatening complication post-CAR-T. In addition to symptomatic measures and preemptive broad-spectrum antibiotics, immunomodulators such as tocilizumab and corticosteroids remain the corner stone for the treatment of CRS. Tocilizumab/corticosteroids-resistant CRS associated with haemophagocytosis markers (spleen and liver enlargement, hyperferritinaemia>10,000ng/mL, hypofibrinogenemia…) should direct the diagnosis towards an overlapping CRS/MAS. An adapted treatment will be based on high-dose IV anakinra and corticosteroids and chemotherapy with etoposide at late refractory stages. These complications and others delignate the need of close collaboration with an intensive care unit., (Copyright © 2021 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results